Abstract
Pancreatic Cancer occupies the fourth position in deaths caused by malignant neoplastic diseases and exhibits high metastasis progression rates to organs including the liver. Such facts are related to reserved prognosis for patients affected by this disease, leading to a medium survival periods of only 6 months. In modern nanomedicine, theranostic nanocarriers are in the front-line search…